

CBSA NEWS IN REVIEW



A BRIEF OVERVIEW OF COLORADO'S MEDICAL DEVICE AND BIOPHARMA INDUSTRIES

Vol. I No. XXVII 23 August – 29 August

COMPANY SPOTLIGHT

- Inc.com for the second consecutive years has included **Baxa Corporation** (Englewood) in its annual ranking of the 5,000 fastest-growing private companies in the US. Baxa ranked number 4,611. The company has grown steadily since its founding in 1975 and currently employs more than 450 associates through its Colorado headquarters and UK subsidiary offices. The Inc. 5,000 list is an extension of Inc. magazine's annual 500 list, and covers businesses that are too big to grow at the pace required to make the Inc. 500 list.
- The FDA has approved **Amgen's** (Boulder/Longmont) drug Nplate™ (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic immune thrombocytopenic purpura. Nplate™, the first FDA-approved pepti-body protein, works by raising and sustaining platelet counts, representing a novel approach for the long-term treatment of this chronic disease.
- **Replidyne** (Louisville) announced they will cut 80 percent of its remaining workforce, leaving the biotech company with just five employees. The 19 workers will be let go in September and October and will incur approximately \$3.1M in expenses including \$1.6M in cash for employee-related severance benefits. In addition, Replidyne will suspend further development of its remaining two drug candidates.
- **Array BioPharma** (Boulder) announced that its Chief Executive Officer, Robert E. Conway, will speak at the Thomas Weisel Partners 2008 Healthcare Conference on 3 September 3 in Boston.
- **Allos Therapeutics** (Westminster) announced that members of the Company's senior management will present a corporate overview at the NewsMakers in the Biotech Industry Conference, co-presented by BioCentury and Thomson Reuters, in New York. The presentation will take place September 4 and a live webcast of the presentation will be available via webcast. The talk will be available via webcast.
- **Covidien** (Boulder) announced the agenda for its investor meeting on 10 September in New York.

FINANCE

- **QLT** (Ft. Collins) announced it has entered into an exclusive license agreement with Reckitt Benckiser Pharmaceuticals for its Atrigel® sustained-release drug delivery technology. Under terms of the agreement QLT received an upfront payment of \$25M and may receive milestone payments of up to \$5M based on the successful development of two Atrigel-formulated products. As part of the transaction, Reckitt acquired 18 employees from QLT and will take over the Ft. Collins facility.
- **Covidien** (Boulder), announced that it has established Covidien Ventures, a corporate venture capital function. Covidien Ventures will invest in areas of strategic importance to the Company with the goal of providing early exposure to innovative technologies and enhancing market intelligence in healthcare products. Covidien Ventures will be managed by Daniel T. Sheehan, Vice President of Corporate Venture Capital, who recently joined Covidien from Affinity Capital Management.

- **Quest Product Development** (Wheat Ridge), a specialized medical device product development company, with the University of Colorado as partner, has been awarded a \$1M STTR grant by the NIH for the development of MicroFlex endoscopes which may allow active control over the shape of the scope for use in minimally invasive surgery. Development is being done in concert by labs from CU Boulder, the Anschutz Medical campus and Quest.

PEOPLE

- **RMC Pharmaceutical Solutions** (Longmont) announced the addition of **Michael Klein, Ph.D.**, as Senior Consultant. Dr. Klein will be located in Thousand Oaks, California, expanding RMC's service in the areas of analytical sciences and product quality. Previously, Dr. Klein was Director of Analytical Sciences and Quality Control at Xencor and prior to that held several positions in Process and Analytical Sciences and in Quality at Amgen.

SQUARE PEGS

- ***Don't miss out on the next gala **BioBeers** bio-networking event 7:00pm 3 September. For more information and to RSVP be certain to visit <http://BioBeers.com>.
- **The CBSA's Bioscience Bogey** is filling up fast. Make sure to register to play by 8 September. Please visit: www.cobiosciencebogey.com/
- Organizers of BioWest 2008 are seeking candidates for the Venture Showcase Award. Six companies will be chosen to present at the showcase on 13 November and will be judged by a panel of national venture capitalists. Deadline for entry is 10/1. To apply, visit www.biowestconference.com/showcase.php.